Purple Book product · Reference 351(a)
KEBILIDI
eladocagene exuparvovec-tneq
At a glance
Nov 13, 2024
Approved
Reference 351(a)
License type
Rx
Marketing
No
Patents listed
Key dates
Approval
Approval date of this BLA submission.
Nov 13, 2024
1 yr 7 mo ago
Today
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
Nov 13, 2031
in 5 yr 6 mo
Pharmaceutical detail
Strength
5.6x10^11VG/ML
Dosage form
Suspension
Route
Intraputaminal
Presentation
Single-Dose Vial
Center
CBER
License number
2168
Product number
001
Submission type
Original
Supplement number
0
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. Biosimilars and interchangeables referencing it are listed below.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Taxonomy and ontology
10 termscenter
Center for Biologics Evaluation and Research
center · CBER
application pathway
Biologics License Application
blaNumber · BLA
license type
351(a)
blaType · 351(a)
application pathway
Section 351(a) Biologic
blaType · 351(a)
product role
Reference or Standalone Biologic
blaType · Reference product
marketing status
Prescription
marketingStatus · Rx
licensure status
Licensed
licensure · Licensed
source kind
Monthly Download
sourceKind · monthly_download
patent status
No Patent List Provided
patentListProvided · No patent list
exclusivity type
Orphan Exclusivity
orphanExclusivityExpirationDate · Orphan Exclusivity
- Food and Drug Administrationparent ofCenter for Biologics Evaluation and Research
- Food and Drug Administrationsource forMonthly Download
- Biologics License Applicationparent ofSection 351(a) Biologic
- Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
- Section 351(a) Biologicmaps to351(a)
- 351(a)classifiesReference or Standalone Biologic
Source provenance
